Latest Headlines

Latest Headlines

Elan deal rumors fly; investors not enthused

No sooner did Elan announce that it was evaluating its " strategic alternatives " than rumors began moving markets. The Danish pharma Lundbeck quickly arose as a possible suitor, on the flimsy evidence

Elan triggers strategic review, spurring merger buzz

Hit by harsh criticism of its handling of Tysabri and disappointing results on its experimental Alzheimer's drug, Ireland's Elan has initiated a strategic review that may lead straight to a sale or

Elan shareholders file lawsuit

Elan shareholders have filed a class action suit against the company. The biotech is being accused of making false and misleading statements regarding the development of the Alzheimer's drug

Alzheimer's drug results boost Elan, Wyeth

Wyeth and Elan's shares were up today as the companies announced potentially promising results from a phase II trial of bapineuzumab, an Alzheimer's treatment. The study did not attain statistical